Lilly's Alimta combination cancer therapy fails trial

Sept 6 Thu Sep 6, 2012 9:33am EDT

Sept 6 (Reuters) - Eli Lilly and Co said a late-stage trial testing its lung cancer drug Alimta failed to meet the main study goal of improving overall survival of patients.

Patients on the trial, named Pointbreak, were given either a combination of Alimta and Roche Holding AG's cancer drug Avastin along with chemotherapy, or just Avastin along with chemotherapy drugs.

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.